Sitagliptin

• CAT Number: I003712
• CAS Number: 486460-32-6
• Molecular Formula: C16H15F6N5O
• Molecular Weight: 407.31
• Purity: ≥95%
• Target: DPP4
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
• InChI: InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
• InChIKey: MFFMDFFZMYYVKS-SECBINFHSA-N
• SMILES: C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N

Sitagliptin（Cat No.:I003712）is an oral antidiabetic drug that selectively inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme responsible for degrading incretin hormones. By inhibiting DPP-4, sitagliptin increases the levels of incretins, which enhance insulin secretion and reduce glucagon release, thereby improving blood glucose control in patients with type 2 diabetes. Sitagliptin is widely used as a monotherapy or in combination with other antidiabetic agents. Its efficacy in improving glycemic control, along with a favorable safety profile, makes it a key therapeutic option in diabetes management.

Reference

[1]. Thomas, L., et al., (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther, 2008. 325(1): p. 175-82.
[2]. Kim, S.J., et al., Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes, 2009. 58(3): p. 641-51.
[3]. Sangle, G.V., et al., Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinology, 2012. 153(2): p. 564-73.
[4]. Kim, S.J., et al., Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes, 2008. 57(5): p. 1331-9.
[5]. Beconi, M.G., et al., Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos, 2007. 35(4): p. 525-32.